Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-951 in Healthy Subjects
NCT04486950Phase 1Completed
- Sponsor
- Takeda
- Start
- Jul 2020
- Primary completion
- May 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-951 in nausea ((none)) and Vomiting (3 cohorts), sponsored by Takeda. Primary endpoints: Treatment-emergent Adverse Events, Clinically Significant Change in Vital Signs and 3 more. Started Jul 2020; status: completed.
02
Drugs
TAK-951
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT04486950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04486950.